 |
|
|
|
April 2007 Cover
|
|
HIV-infected patients who initiate therapy with a CD4 cell count above 350 are far more likely to return to a "nearly normal" CD4 cell count than patients who initiate therapy with a CD4 cell count below 350, according to
a study by the Johns Hopkins University School of Medicine. The 655-patient observational study followed patients for a median of 46 months; it found that all patients generally experienced a significant CD4 cell increase
during their first year of therapy and eventually plateaued. However, patients who began HAART with a baseline CD4 cell count above 350 had a higher plateau CD4 cell count than patients who began HAART with a baseline CD4
cell count below 350. In their conclusion, the researchers explicitly recommend that HAART initiation be considered while a patient's CD4 cell count is still above 350. from TheBodyPro.com
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
